NYXOAH SA (NYXH) Fundamental Analysis & Valuation

NASDAQ:NYXH • BE0974358906

Current stock price

3.29 USD
+0.33 (+11.15%)
Last:

This NYXH fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. NYXH Profitability Analysis

1.1 Basic Checks

  • NYXH had negative earnings in the past year.
  • NYXH had a negative operating cash flow in the past year.
  • NYXH had negative earnings in each of the past 5 years.
  • In the past 5 years NYXH always reported negative operating cash flow.
NYXH Yearly Net Income VS EBIT VS OCF VS FCFNYXH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M -80M

1.2 Ratios

  • NYXH has a Return On Assets of -76.04%. This is in the lower half of the industry: NYXH underperforms 77.13% of its industry peers.
  • Looking at the Return On Equity, with a value of -183.36%, NYXH is doing worse than 75.00% of the companies in the same industry.
Industry RankSector Rank
ROA -76.04%
ROE -183.36%
ROIC N/A
ROA(3y)-49.41%
ROA(5y)-37.16%
ROE(3y)-93.25%
ROE(5y)-64.86%
ROIC(3y)N/A
ROIC(5y)N/A
NYXH Yearly ROA, ROE, ROICNYXH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150 -200

1.3 Margins

  • Looking at the Gross Margin, with a value of 63.13%, NYXH is in the better half of the industry, outperforming 67.55% of the companies in the same industry.
  • In the last couple of years the Gross Margin of NYXH has grown nicely.
  • NYXH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 63.13%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.22%
GM growth 5Y2.24%
NYXH Yearly Profit, Operating, Gross MarginsNYXH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -5K -10K -15K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. NYXH Health Analysis

2.1 Basic Checks

  • NYXH does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for NYXH has been increased compared to 1 year ago.
  • Compared to 5 years ago, NYXH has more shares outstanding
  • The debt/assets ratio for NYXH is higher compared to a year ago.
NYXH Yearly Shares OutstandingNYXH Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
NYXH Yearly Total Debt VS Total AssetsNYXH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of -4.60, we must say that NYXH is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -4.60, NYXH is doing worse than 71.28% of the companies in the same industry.
  • NYXH has a Debt/Equity ratio of 0.37. This is a healthy value indicating a solid balance between debt and equity.
  • NYXH has a Debt to Equity ratio of 0.37. This is comparable to the rest of the industry: NYXH outperforms 46.28% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.37
Debt/FCF N/A
Altman-Z -4.6
ROIC/WACCN/A
WACC6.69%
NYXH Yearly LT Debt VS Equity VS FCFNYXH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M

2.3 Liquidity

  • NYXH has a Current Ratio of 1.25. This is a normal value and indicates that NYXH is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.25, NYXH is doing worse than 85.64% of the companies in the same industry.
  • NYXH has a Quick Ratio of 1.16. This is a normal value and indicates that NYXH is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Quick ratio value of 1.16, NYXH is not doing good in the industry: 75.00% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.25
Quick Ratio 1.16
NYXH Yearly Current Assets VS Current LiabilitesNYXH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. NYXH Growth Analysis

3.1 Past

  • The earnings per share for NYXH have decreased strongly by -31.24% in the last year.
  • The Revenue has grown by 121.63% in the past year. This is a very strong growth!
  • Measured over the past years, NYXH shows a very strong growth in Revenue. The Revenue has been growing by 170.65% on average per year.
EPS 1Y (TTM)-31.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-26.57%
Revenue 1Y (TTM)121.63%
Revenue growth 3Y48.11%
Revenue growth 5Y170.65%
Sales Q2Q%346.87%

3.2 Future

  • NYXH is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.04% yearly.
  • Based on estimates for the next years, NYXH will show a very strong growth in Revenue. The Revenue will grow by 112.36% on average per year.
EPS Next Y18.35%
EPS Next 2Y18.34%
EPS Next 3Y18.04%
EPS Next 5YN/A
Revenue Next Year253.2%
Revenue Next 2Y181.36%
Revenue Next 3Y142.13%
Revenue Next 5Y112.36%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
NYXH Yearly Revenue VS EstimatesNYXH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
NYXH Yearly EPS VS EstimatesNYXH Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 -0.5 -1 -1.5 -2

More info and screens

Find the best growth stocksShow best growing peers

0

4. NYXH Valuation Analysis

4.1 Price/Earnings Ratio

  • NYXH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NYXH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NYXH Price Earnings VS Forward Price EarningsNYXH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NYXH Per share dataNYXH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

  • NYXH's earnings are expected to grow with 18.04% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.34%
EPS Next 3Y18.04%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NYXH Dividend Analysis

5.1 Amount

  • No dividends for NYXH!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NYXH Fundamentals: All Metrics, Ratios and Statistics

NYXOAH SA

NASDAQ:NYXH (4/14/2026, 12:17:58 PM)

3.29

+0.33 (+11.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-19
Earnings (Next)05-12
Inst Owners21.41%
Inst Owner Change0.38%
Ins Owners19.69%
Ins Owner ChangeN/A
Market Cap143.64M
Revenue(TTM)10.02M
Net Income(TTM)-90.08M
Analysts81.43
Price Target11.26 (242.25%)
Short Float %1.12%
Short Ratio5.57
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-5.26%
Min EPS beat(2)-5.5%
Max EPS beat(2)-5.02%
EPS beat(4)1
Avg EPS beat(4)-6.88%
Min EPS beat(4)-22.16%
Max EPS beat(4)5.16%
EPS beat(8)4
Avg EPS beat(8)-3.24%
EPS beat(12)6
Avg EPS beat(12)-2.51%
EPS beat(16)9
Avg EPS beat(16)-3.04%
Revenue beat(2)1
Avg Revenue beat(2)9.67%
Min Revenue beat(2)-1.3%
Max Revenue beat(2)20.65%
Revenue beat(4)1
Avg Revenue beat(4)-5.12%
Min Revenue beat(4)-38.43%
Max Revenue beat(4)20.65%
Revenue beat(8)1
Avg Revenue beat(8)-16.45%
Revenue beat(12)2
Avg Revenue beat(12)-18.81%
Revenue beat(16)2
Avg Revenue beat(16)-27.83%
PT rev (1m)-0.19%
PT rev (3m)0.4%
EPS NQ rev (1m)0.1%
EPS NQ rev (3m)-3.36%
EPS NY rev (1m)10.62%
EPS NY rev (3m)8.95%
Revenue NQ rev (1m)10.01%
Revenue NQ rev (3m)30.26%
Revenue NY rev (1m)3.31%
Revenue NY rev (3m)5.39%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.27
P/FCF N/A
P/OCF N/A
P/B 2.5
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.76
EYN/A
EPS(NY)-2.26
Fwd EYN/A
FCF(TTM)-1.87
FCFYN/A
OCF(TTM)-1.85
OCFYN/A
SpS0.27
BVpS1.31
TBVpS-0.03
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -76.04%
ROE -183.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 63.13%
FCFM N/A
ROA(3y)-49.41%
ROA(5y)-37.16%
ROE(3y)-93.25%
ROE(5y)-64.86%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.22%
GM growth 5Y2.24%
F-Score2
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity 0.37
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 17.95%
Cap/Sales 8.03%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.25
Quick Ratio 1.16
Altman-Z -4.6
F-Score2
WACC6.69%
ROIC/WACCN/A
Cap/Depr(3y)55.58%
Cap/Depr(5y)60.2%
Cap/Sales(3y)30.43%
Cap/Sales(5y)58.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-31.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-26.57%
EPS Next Y18.35%
EPS Next 2Y18.34%
EPS Next 3Y18.04%
EPS Next 5YN/A
Revenue 1Y (TTM)121.63%
Revenue growth 3Y48.11%
Revenue growth 5Y170.65%
Sales Q2Q%346.87%
Revenue Next Year253.2%
Revenue Next 2Y181.36%
Revenue Next 3Y142.13%
Revenue Next 5Y112.36%
EBIT growth 1Y-40.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-2.08%
EBIT Next 3Y4.93%
EBIT Next 5YN/A
FCF growth 1Y-38.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-40.13%
OCF growth 3YN/A
OCF growth 5YN/A

NYXOAH SA / NYXH Fundamental Analysis FAQ

What is the fundamental rating for NYXH stock?

ChartMill assigns a fundamental rating of 2 / 10 to NYXH.


What is the valuation status of NYXOAH SA (NYXH) stock?

ChartMill assigns a valuation rating of 0 / 10 to NYXOAH SA (NYXH). This can be considered as Overvalued.


What is the profitability of NYXH stock?

NYXOAH SA (NYXH) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for NYXH stock?

The Earnings per Share (EPS) of NYXOAH SA (NYXH) is expected to grow by 18.35% in the next year.